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Abstract: Atrial fibrillation is the most common of the cardiac arrhythmias and is associated with 
high risk of stroke and systemic thromboembolism. Prevention of these complications is therefore 
a major component of clinical management in patients with this rhythm disorder. The choice of 
antithrombotic therapy in any given patient depends on his or her risk profile and needs to be 
carefully balanced against the risk of bleeding. In this review we discuss the pathophysiology 
of thrombogenesis in atrial fibrillation, risk factors for systemic thromboembolism in atrial 
fibrillation, patient risk stratification modules both for systemic thromboembolism and the risk 
of bleeding, current antithrombotic therapy strategies, clinicoepidemiological evidence that led 
to their evolvement, the challenges that plague them, recent developments in the field and how 
they could possibly affect our future clinical decision making.
Keywords: atrial fibrillation, systemic thromboembolism, thromboembolism, vitamin K 
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Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in the 
clinical settings. The Framingham Heart Study showed the lifetime risk of AF for 
adults older than 40 years is 26% for men and 23% for women.1 Estimated prevalence 
of AF in the United States was in excess of 2.2 million in 2001 with an incidence of 
70,000 new cases per year.2 The prevalence increases steeply as the population ages 
and per Go et al it is expected to increase upwards of 5.3 million by the year 2050 
(Figure 1).2 Much of morbidity and mortality associated with AF is a result of systemic 
thromboembolic (STE) complications, mainly affecting the cerebrovascular system.3 
The risk of stroke increases five-fold in people with AF4 and is the same across the 
spectrum of paroxysmal, persistent, and permanent AF.5 It has been reported that AF 
accounts for more than 15% of all strokes and is the most common cause of ischemic 
stroke in women older than 75 years of age.6,7 It is also known that AF associated 
strokes are more severe compared to those from other causes, thereby conferring 
an increased risk of morbidity, mortality, and poor functional outcome.4 Therefore, 
while the treatment of arrhythmia per se is important, measures to prevent STE are 
equally important if not more, as far as management of patients with this arrhythmia 
is concerned. Despite in-depth and sound clinical evidence from multiple randomized 
trials, antithrombotic therapy in AF patients has been challenging. In this review, we 
plan to discuss some of these challenges, recent developments in the field, and how 
they could possibly affect our current and future clinical decision-making.
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Methods
This review is based on a systematic search of published 
literature on the topic to date.
AF and stroke
Mechanism
Thromboembolism in AF has been linked to several underly-
ing pathophysiologic mechanisms. These mechanisms involve 
flow abnormalities as evidenced by “stasis” mainly in the 
left atrial appendage, the most common site of thrombus 
formation in patients with AF.8 Endomyocardial dysfunction/
disruption caused by progressive dilation of the left atrium 
in patients with AF, as well as abnormalities of blood con-
stituents and inflammatory and growth factor abnormalities, 
are thought to result in a substrate for thrombosis.9 Due to a 
combination of these factors, AF patients are at higher risk 
of developing thromboembolic complications even when in 
sinus rhythm.10
Risk factors for thromboembolism 
in AF
Currently reported clinical and echocardiographic risk 
factors for increased risk of thromboembolism in AF 
patients have been mainly derived from cohort data and 
non-warfarin arms of older clinical trials. While the list 
of these risk factors is long, it only includes those which 
were documented in the studies, leaving out other potential 
ones which were not systematically studied and have been 
reported in various contemporary studies since.11 Two recent 
systematic reviews reviewed all the reported risk factors and 
identified commonly accepted factors.12,13 The list included: 
prior history of stroke/transient ischemic attack (TIA)/
thromboembolism, advanced age, hypertension, diabetes, 
structural heart disease, heart failure, and/or systolic 
dysfunction. While these risk factors help clinicians to 
determine the individual risk of their patients, there are some 
caveats and inconsistencies that need to be considered. Age is 
not a “yes/no” phenomenon as the risk of thromboembolism 
increases with increasing age. Hypertension as a risk factor in 
most of the older trials was either uncontrolled hypertension 
or use of antihypertensive medications, whether or not 
medically controlled hypertension poses an equal risk of 
thromboembolism is not known. Also, heart failure mainly 
referred to systolic heart failure and risk posed by heart 
failure with preserved systolic function is not reported and 
hence, not known.11
Risk stratification
As reported in the aforementioned systematic reviews, stroke 
risk in AF patients is not homogenous. It varies significantly 
based on the presence or absence of certain high-risk features 
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Figure 1 Projected number of adults with atrial fibrillation in the United States.2
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and a combination thereof. Due to the heterogeneous nature 
of stroke risk and bleeding complications associated with 
antithrombotic therapies several risk stratification models 
(RSMs) have been proposed over the years.12 While the earlier 
RSMs artificially categorized risk into low, moderate, and 
severe, the more recent ones have opted for a point-based 
system, realizing that the risk of thromboembolism in AF 
is a continuum. The most widely used, easy to remember, 
and most validated of these models is the CHADS2 score, 
which evolved from the Stroke Prevention in Arial Fibrilla-
tion (SPAF) investigators criteria.14 CHADS2, which stands 
for Congestive heart failure, Hypertension, Age ≥75 years, 
Diabetes, and Stroke, assigns 1 point each to the first four 
and 2 points to the history of stroke or TIAs. Studies have 
validated that the risk of thromboembolic events increases 
proportionally to the increase in the CHADS2 score 
(Table 1).14–16 Furthermore, treatment with oral anticoagu-
lation (OAC) therapy reduces the risk of thromboembolism 
for all except those with a CHADS2 score of “0” where the 
bleeding risk outweighed the benefits.15 Despite being widely 
used CHADS2 scoring system has been criticized. First, 
the ability of CHADS2 score to predict thromboembolic 
risk in patients with AF is limited and comparable to other 
previously described RSMs.17 Second, it doesn’t take into 
consideration other stroke risk factors/stroke risk modifiers 
like female gender, age 65–75 years, and history of vascular 
disease, that need to be considered for a more comprehensive 
stroke risk assessment. Third, it categorizes large numbers 
of people into “moderate risk” with a score of “1,” which 
per societal guidelines up until recently could be treated 
with either aspirin or vitamin K antagonists (VKAs).3 The 
third point seems a little discomforting in light of reports 
showing that therapy with VKAs is superior to antiplatelet 
therapy in patients with “moderate risk” with no increased 
risk of bleeding,18 and that antiplatelet prescriptions are not 
always associated with lower adverse events.19 Fourth, the 
CHADS2 score does not incorporate information obtained 
from cardiac imaging with transesophageal echocardio-
graphy (ECHO) – left atrial appendage thrombus, complex 
aortic plaque, spontaneous ECHO contrast, and reduced left 
atrial appendage velocities, which have all been shown to be 
independent predictors of stroke and thromboembolism in 
AF patients.20 To deal with some of these drawbacks a new 
RSM model has been proposed called the Birmingham 2009 
and NICE schema with an acronym CHA2DS2-VASc.17 
CHA2DS2-VASc score stands for: Congestive heart failure, 
Hypertension, Age ≥75 years, Diabetes, Stroke/TIA, Vascular 
disease, Age 65–75 years, and Sex category (female gender). 
It assigns 2 points each to age ≥75 years and history of stroke/
TIA and 1 point each to the rest for a total possible score of 9 
points (Table 2). When applied to a real world AF cohort of 
patients from the European Heart Survey, CHA2DS2-VASc 
fared marginally better than CHADS2 (c statistic of 0.606 
versus 0.586). However, compared to the CHADS2 score 
it categorized low risk patients much better (event rate of 
0 versus 1.4%), the numbers, however, were low. The rate 
of thromboembolic events increased in proportion to the 
CHA2DS2-VASc score (Table 3).21
Clinical utility of antithrombotic 
therapy in patients with AF
Extensive clinical data from multiple trials have provided 
enough evidence for the use of antithrombotic therapy in AF 
patients both for primary and secondary prevention of stroke 
and thromboembolic events.
Adjusted dose vKAs therapy  
versus placebo or control
Six large randomized trials published between 1989 and 1992, 
AFASAK 1,22 BAATAF,23 SPAF 1,24 CAFA,25 SPINAF,26 
and EAFT,27 evaluated the role of adjusted dose VKAs 
against placebo in the prevention of stroke/thromboembolism 
Table 1 CHADS2 score and stroke rate4–16
Score (points) Adjusted stroke rate (% per year)   
with 95% confidence interval
0 1.9 (1.2–3.0)
1 2.8 (2.0–3.8)
2 4.0 (3.1–5.1)
3 5.9 (4.6–7.3)
4 8.5 (6.3–11.1)
5 12.5 (8.2–17.5)
6 18.2 (10.5–27.4)
Notes:  CHADS2  –  congestive  heart  failure;  hypertension;  age  ≥  75;  diabetes 
mellitus; stroke (doubled). 
Table 2 CHA2DS2-vASc score17
Risk factor Score
Congestive heart failure/Lv dysfunction 1
Hypertension 1
Age . 75 2
Diabetes mellitus 1
Stroke/TiA/thromboembolism 2
Vascular disease* 1
Age 65–74 1
Sex category (ie, female sex) 1
Maximum score 9
Note: *Prior myocardial infarction; peripheral artery disease; aortic plaque.
Abbreviations: Lv, left ventricular; TiA, transient ischemic attack.
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in patients with non-valvular AF. All except the EAFT trial 
were primary prevention trials. According to a meta-analysis 
of these trials, adjusted dose VKAs were associated with 
64% relative risk (RR) reduction of all strokes compared to 
placebo conferring an absolute risk reduction of 2.7% per 
year in the primary prevention group and 8.4% per year in the 
secondary prevention group. The RR reduction was higher 
(67%) when only ischemic strokes were considered. The 
results were similar for varying severities of stroke, disabling 
versus non-disabling. Adjusted dose VKAs were associated 
with reduction in all-cause mortality by 26%.28
Antiplatelet therapy versus placebo  
or control
Eight randomized trials published between 1989 and 2006, 
AFASAK I,22 SPAF I,24 EAFT,27 ESPS II,29 LASAF,30 
UK-TIA,31 JAST,19 and SAFT,32 compared antiplatelet 
therapy mainly comprising of aspirin versus placebo or no 
treatment for primary and/or secondary prevention of strokes 
in AF patients. The aspirin dose in these trials varied from 
50 mg to 1300 mg per day. Systematic analysis of the trials 
showed that aspirin use is associated with a 19% RR reduc-
tion of strokes with an absolute risk reduction of 0.8% per 
year in the primary and 2.5% per year in the secondary pre-
vention trials. Available data from four of these trials showed 
that aspirin was associated with a 13% reduction in disabling 
strokes and a 29% reduction in non-disabling strokes. When 
only ischemic strokes were looked at, aspirin use resulted in 
a 22% RR of strokes.28 A large part of the beneficial effect of 
aspirin noted in this meta-analysis is driven by SPAF I trial 
results which showed that aspirin 325 mg use was associated 
with a 42% RR reduction of strokes when compared with 
placebo. The trial, however, showed internal heterogeneity 
in the warfarin eligible (RR reduction of 94%) versus the 
non-warfarin eligible patients (RR reduction of 8%).24 In 
the Japanese Atrial Fibrillation Stroke Trial, use of aspirin 
in people with lone AF was associated with increased 
primary outcomes (3.1% versus 2.4% per year) with a 
slightly increased, although statistically non-significant risk 
of increased major bleeds.19
vKAs versus antiplatelet therapy
Warfarin or other oral VKAs have been compared with 
varying doses of aspirin alone in nine randomized trials: 
AFASAK I,22 EAFT,27 SPAF II,33 AFASAK II,34 PATAF,35 a 
study by Vemmos et al,36 the Chinese ATAFS study,37 and 
WASPO.38 Three randomized trials compared warfarin/
oral VKAs with other antiplatelet agents: indobufen in 
SIFA trial,39 triflusal in NASPEAF trial,40 and aspirin + 
clopidogrel in the ACTIVE W trial.41 On the basis of these 
twelve trials, warfarin/oral VKAs were associated with 
a 37% RR reduction of strokes compared to antiplatelet 
agents.28 The ACTIVE W trial showed that therapy with 
VKAs was superior to aspirin + clopidogrel combination 
therapy (RR reduction by 40%) and was associated with 
significantly lower risk of bleeding.41 The ACTIVE-A arm 
of the trial showed that aspirin and clopidogrel combination 
therapy was superior to monotherapy with aspirin (28% RR 
of strokes), in those deemed unsuitable for VKA therapy.42 
Major bleeding with the combination therapy was, however, 
noted to be high (2.0% versus 1.3% per year).
Combination vKAs and antiplatelet 
therapy
Since the combination of anticoagulant and antiplatelet 
agents improved outcomes in patients with acute coronary 
syndrome,43 it was intuitive to think that the same would 
apply to patients with AF with high-risk features. However, 
a meta-analysis by Dentali et al which looked at several 
studies with various indications for VKAs, concluded that 
combination therapy with oral VKAs and antiplatelet agents 
reduced thromboembolic complications only in patients with 
mechanical heart valves. There was no difference in risk of 
thromboembolism in patients with AF with the combination 
therapy (odds ratio 0.99, 95% confidence interval 0.47–2.07). 
There was no difference in all-cause mortality with VKAs 
alone versus VKAs plus antiplatelet therapy (odds ratio 
0.98, 95% confidence interval 0.77–1.25), however, there 
was a significant increase in bleeding risk with the com-
bination therapy (odds ratio 1.43, 95% confidence interval 
1.00–2.02).44
Table 3 CHA2DS2-vASc score and stroke rate21
Score (points) Adjusted stroke  
rate (% per year)
0 0
1 1.3
2 2.2
3 3.2
4 4.0
5 6.7
6 9.8
7 9.6
8 6.7
9 15.2
Notes: CHA2DS2-vASc – congestive heart failure/left ventricular dysfunction; 
hypertension; age ≥ 75; diabetes mellitus; stroke/transient ischemic attack/
thromboembolism; vascular disease (prior myocardial infarction, peripheral 
artery disease, aortic plaque); age 65–74; sex category (female sex).
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Bleeding risk
It is evident from the above discussion that OAC therapy 
with adjusted dose VKAs is far superior to aspirin/antiplatelet 
agents in reducing thromboembolic events and all-cause 
mortality in patients with AF. This benefit, however, came 
at a price of increased bleeding risk, especially the dreaded 
complication of intracranial hemorrhage. Systematic review 
of the trials mentioned above showed that the risk of intra-
cranial bleeds more than doubled in patients on adjusted dose 
VKAs compared to aspirin/antiplatelet agents. The absolute 
increase in risk was, however, small at 0.2% per year.28 These 
findings were, however, challenged by two recent trials, 
which showed either no difference in the risk of major bleeds 
(BAFTA),45 or even reduced rate of major bleeds (WASPO)38 
with adjusted dose VKAs compared to aspirin. These results 
could reflect lower anticoagulation intensity, more careful 
dosing, or better control of hypertension in OAC patients in 
the contemporary settings.11
Given the increased risk of bleeding with antithrombotic 
therapies, it is generally perceived that a bleeding risk 
assessment should be performed in all AF patients before 
they are prescribed VKAs or antiplatelet therapy.46 Several 
RSMs have been proposed to calculate the bleeding risk in 
patients on OAC therapy with VKAs over the years.47 These 
schemes either did not focus on AF patients,48,49 looked at 
only a specific cohort of AF patients,50 or incorporated risk 
factors that are not routinely available.51 Hence, none of 
them have been widely validated, commonly used, or recom-
mended in AF management guidelines. Pisters et al proposed 
a new schema called the HAS-BLED score, using the real 
world AF patients from the European Heart Survey.47 The 
score, which assigns 1 point each for Hypertension, Abnor-
mal liver and/or renal function, Stroke history, Bleeding 
history or predisposition, Labile international normalized 
ratio [INR], Elderly (age .65), and Drugs/alcohol usage, 
for a total possible score of 9 points (Table 4), showed an 
increase in the annual bleeding rate with an increasing score 
in the derivation cohort.47 The HAS-BLED score showed 
better predictive accuracy compared to the previously pro-
posed scores in a validation study performed by authors on 
the SPORTIF III and V trial patients.52 Since it is easy to 
remember, uses readily available clinical parameters, and 
fares better in terms of predictive accuracy compared to 
the other available bleeding RSMs, the European Society 
of Cardiology has incorporated the HAS-BLED score in 
their current AF management guidelines. They recommend 
that a score of $3 would indicate “high risk,” and that some 
caution and regular review of the patient would be needed 
following the initiation of antithrombotic therapy, whether 
with VKAs or aspirin.11
Since the publication of the HAS-BLED score, another 
simple and easy to use bleeding risk stratification score 
has been proposed and validated by the investigators of the 
ATRIA study.53 The ATRIA hemorrhage risk score includes 
five commonly available clinical parameters: anemia 
(3 points), severe renal disease (3 points), age $75 years 
(2 points), prior bleeding (1 point), and hypertension (1 point; 
Table 5). The score was derived and validated in a large cohort 
of AF patients enrolled and followed in Kaiser Permanente, 
a large integrated health care system in Northern California, 
USA. The hemorrhage rates increased as the score increased 
from 0.4% per year in patients with a score of “0” to 17.3% 
per year in those with a score of “10”. When collapsed into 
three categories, the hemorrhage rates were 0.8% per year in 
the low risk (score 0–3), 2.6% per year in the intermediate 
Table 4 HAS-BLED bleeding risk score47
Letter Clinical characteristic Points
H Hypertension 1
A Abnormal renal and liver function  
(1 point each)
1 or 2
S Stroke 1
B Bleeding 1
L Labile iNRs 1
E Elderly (age . 65) 1
D Drugs or alcohol (1 point each) 1 or 2
Maximum score of 9
Notes:  Hypertension,  systolic  blood  pressure  .160  mmHg;  abnormal  kidney 
function,  presence  of  chronic  dialysis  or  renal  transplantation  or  serum 
creatinine  $200  mmol/L;  abnormal  liver  function,  chronic  hepatic  disease 
(eg,  cirrhosis)  or  biochemical  evidence  of  significant  hepatic  derangement 
(eg,  bilirubin  .2  ×  upper  limit  of  normal,  in  association  with  aspartate 
aminotransferase/alanine aminotransferase/alkaline phosphatase .3 × upper limit 
normal, etc); bleeding, previous bleeding history and/or predisposition to bleeding, 
eg, bleeding diathesis, anaemia, etc; labile iNRs, unstable/high iNRs or poor time in 
therapeutic range (eg, ,60%); drugs/alcohol use, concomitant use of drugs, such as 
antiplatelet agents, non-steroidal anti-inflammatory drugs, or alcohol abuse, etc.
Abbreviation: iNR, international normalized ratio.
Table 5 ATRiA hemorrhage risk score53
Clinical characteristic Score
Anemia* 3
Severe renal disease** 3
Age . 75 years 2
Previous bleeding 1
Hypertension 1
Maximum score of 10
Risk category
Low 0–3
intermediate 4
High 5–10
Notes:  *Hemoglobin  ,13  g/dL  in  men  and  ,12  g/dL  in  women;  **estimated 
glomerular filtration rate, 30 mL/min or dialysis-dependent.
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risk (score of 4), and 5.8% per year in the high-risk groups 
(score 5–10). When compared to the previously proposed 
bleeding RSMs, both the continuous and the categorical 
forms of the ATRIA score did better with a c-index of 0.74 
and 0.69, respectively.53
Current recommendations  
for antithrombotic therapy
The current recommendations for antithrombotic therapy 
in patients with AF are based on the presence or absence 
of risk factors, using either the CHADS2 risk stratification 
scheme3,54 or using both the CHADS2 and CHA2DS2-VASc 
schemes,11 as outlined in Tables 6 and 7.
Limitations of OAC therapy  
with VKAs
VKAs produce their antithrombotic effect by preventing the 
gamma carboxylation of vitamin K dependent coagulation 
factors II, VII, IX, and X.55 They have a narrow therapeutic 
window demonstrating an increased risk of stroke at lower 
levels of anticoagulation (INR , 2) and higher incidence of 
intracranial bleeds with INR . 3 (Figure 2).56,57 VKAs also 
have an unpredictable pharmacologic profile in different 
patients, based on genetic factors and multiple food and drug 
interactions.55 To balance the risk of stroke versus the risk 
of bleeding, and to account for varying pharmacokinetics 
and pharmacodynamics, patients on VKAs require closer 
monitoring with frequent dose adjustments, which is chal-
lenging both for the clinicians and the patients in the real 
world.58,59 VKAs have a slower onset and offset of action 
making bridging difficult when patients need to be off OAC 
therapy for a procedure. Hence, despite proven clinical util-
ity in primary and secondary prevention of strokes in AF 
patients, adjusted dose VKA therapy has been underutilized. 
Reported estimates of VKA use amongst eligible AF patients 
varies from 10%–80% depending on the population group 
studied, and the use amongst the eligible elderly patients 
has been consistently reported to be low.60 Due to the above 
stated impediments, even in patients who are on therapy 
with VKAs, the measures of quality anticoagulation therapy, 
namely time spent in therapeutic range with INR between two 
to three has been at best sub-optimal, ∼60% in the settings 
of clinical trial and ∼50% in the real world.61
The limitations of VKAs have long been felt in the sci-
entific community combined with a vigorous effort to look 
for novel anticoagulation agents that would overcome the 
shortcomings of the oral VKA agents. An ideal agent would 
have the following characteristics: orally administrable; 
wide therapeutic window; fixed dose with predictable phar-
macologic profile, and few drug/food interactions obviating 
the need for closer monitoring.62 Several targets have been 
recognized in the coagulation pathway for development of 
novel oral/parenteral anticoagulants (Figure 3).63 Some of 
these went into phase III clinical trials and are discussed in 
the sections below.
Oral direct thrombin inhibitors
Oral direct thrombin inhibitors bind directly to thrombin in 
the final step of the coagulation pathway. This prevents for-
mation of fibrin, thrombin mediated activation of Factors V , 
VII, XI, and XII, and thrombin induced platelet aggregation.62 
Several oral direct thrombin inhibitors have undergone 
Table 6 ACC/AHA/ESC 2006 Guidelines3
High-risk factors Moderate-risk factors Less validated or weaker risk factors
Previous stroke, TiA, or embolism Age greater than or equal to 75 years Female gender
Mitral stenosis Hypertension Hypertension Age 65–74 years
Prosthetic heart valve Heart failure Coronary artery disease
Lv ejection fraction 35% or less Thyrotoxicosis
Diabetes mellitus
Recommendations
No risk factors Aspirin, 81–325 mg daily
One moderate-risk factor Aspirin, 81–325 mg daily, or warfarin  
(iNR 2.0 to 3.0, target 2.5)
Any high-risk factor or more than  
1 moderate-risk factor
warfarin (iNR 2.0 to 3.0, target 2.5)  
(if mechanical valve, target iNR greater than 2.5)
2011 AACF/AHA/HRS focused update54
Dabigatran is useful as an alternative to warfarin for the prevention of stroke and systemic thromboembolism in patients with paroxysmal to 
permanent atrial fibrillation and risk factors for stroke or systemic embolization who do not have a prosthetic heart valve or hemodynamically 
significant valve disease, severe renal failure (creatinine clearance –15 mL/min), or advanced liver disease (impaired baseline clotting function)
Abbreviations: TiA, transient ischemic attack; iNR, international normalized ratio.
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clinical development and two have been studied for stroke 
prevention in AF patients – ximelagatran and dabigatran.
Ximelagatran was one of the first oral direct thrombin 
inhibitors to be studied in phase III clinical trials for stroke 
and STE prevention in AF patients. The drug showed promise 
in terms of being non-inferior to warfarin with a better bleed-
ing profile.64,65 However, several studies showed increased 
hepatotoxicity and adverse cardiovascular events with the 
drug64–67 and hence, it was withdrawn from the market and 
further development stopped in 2006.
The oral direct thrombin inhibitor dabigatran was 
compared to warfarin in the RE-LY trial,68 which had a 
prospective, randomized, open, blinded-endpoint evaluation 
design. Dabigatran 110 mg twice a day was non-inferior to 
warfarin for the primary endpoint of stroke and systemic 
embolism and was associated with 20% fewer major bleeds. 
On the other hand, 150 mg twice-daily dose of dabigatran 
showed superiority compared with warfarin with a 35% less 
stroke and STE and there was no significant difference to 
warfarin in terms of major bleeds. Both doses of dabigatran 
had significantly fewer life-threatening major bleeds and 
significantly fewer intracranial hemorrhages compared with 
  warfarin. The 150 mg arm of the trial showed increased major 
gastrointestinal bleeds, which was statistically significant. 
The authors of the trial attributed this to the acidic milieu 
required for dabigatran absorption and the drug delivery 
system that comprises of drug coated pellets with a tartaric 
acid core. The actual reason, however, remains unknown 
and needs further investigation. There was also a numeri-
cal but nonstatistically significant increase in myocardial 
infarction events in dabigatran-treated patients compared 
with warfarin.68 It is not clear if this is largely an adverse 
effect of dabigatran or a protective effect of warfarin, 
which affects multiple coagulation pathways, compared 
to dabigatran, which only targets thrombin. Similar find-
ings were seen in the SPORTIF III trial, which compared 
ximelagatran with warfarin,64 and the AMADEUS trial 
that compared idraparinux with warfarin.69 However, 
the SPORTIF V trial that also compared ximelagatran 
with warfarin did not show this effect, leaving the above 
explanation uncertain.65 Dabigatran is currently approved 
for usage in stroke prevention in AF patients both in Europe 
and the United States.
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Figure  2  ischemic  stroke  and  intracranial  bleeding  in  relation  to  intensity  of 
anticoagulation.56,57
Table 7 ESC 2010 Guidelines11
Major risk factors Clinically relevant non-major risk factors
Previous stroke, TiA, or embolism Heart failure or moderate to severe systolic dysfunction (eg, LvEF # 40%)
Age greater than or equal to 75 years Hypertension
Diabetes
Female sex
Age 65–74 years
vascular disease+
Recommendations
Risk category CHA2DS2-vASc score Recommended therapy
One major or $2 clinically relevant  
non-major risk factors
$2 Oral anticoagulation therapy* for goal iNR 2–3
1 clinically relevant non-major  
risk factor
1 Either oral anticoagulation therapy* for goal iNR of 2–3 or aspirin  
75–325 mg daily. Preferred: oral anticoagulation therapy rather than aspirin
No risk factor 0 Either aspirin 75–325 mg daily or no antithrombotic therapy.  
Preferred: no antithrombotic therapy rather than aspirin
Notes:  +Prior  myocardial  infarction,  peripheral  artery  disease,  aortic  plaque;  *dabigatran  may  be  considered  as  an  alternative  where  oral  anticoagulation 
therapy is appropriate. Hypertension, Age $ 75, Diabetes mellitus, Stroke/Transient ischemic attack/Thromboembolism, vascular disease, Age 65–74, Sex category 
(female sex).
Abbreviations: TiA, transient ischemic attack; LvEF, left ventricular ejection fraction; iNR, international normalized ratio; CHA2DS2-vASc, congestive heart failure/
Left ventricular dysfunction. 
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Factor Xa (FXa) inhibitors
FXa inhibitors may block FXa directly by binding to its 
active site, thereby preventing its interaction with the sub-
strates or indirectly requiring antithrombin as a cofactor. 
Fondaparinux and idraparinux inhibit FXa indirectly and 
are administered parenterally, while direct FXa inhibitors 
are oral agents at various stages of clinical development and 
include LY517717, YM150, DU-176b, apixaban, betrixaban, 
and rivaroxaban.62 Some of these agents have already been 
evaluated in phase III clinical trials for prevention of stroke 
and STE in AF patients and are discussed below.
The AMADEUS trial compared indirect FXa inhibitor 
idraparinux against adjusted dose VKAs for stroke and 
STE prevention in AF patients. The trial was stopped after 
randomization due to excessive clinically relevant bleeding 
in the idraparinux group.69
The AVERROES trial compared direct FXa inhibitor 
apixaban against aspirin in patients deemed unsuitable for 
warfarin. This trial was stopped early due to very clear 
superiority of apixaban over aspirin, demonstrating a 55% 
reduction in the primary endpoint of stroke and STE. There 
was no significant difference between apixaban and aspirin 
as far as major bleeds and intracranial hemorrhage was 
concerned. Apixaban was better tolerated than aspirin with 
a permanent discontinuations rate of 17.9% per year against 
20.5% per year with aspirin.70
ROCKET AF trial was a double-blind, double-dummied 
design in 14,200 patients, and aimed to achieve non-inferiority 
when comparing direct FXa inhibitor rivaroxaban against 
warfarin. The trial did achieve its goal of non-inferiority in 
the on treatment (hazard ratio 0.79, P , 0.001) and intention 
to treat analysis (hazard ratio 0.88, P , 0.001).71 The FDA 
recently approved rivaroxaban for use in prevention of stroke 
and STE in AF patients.
ARISTOTLE, a double-blind, double-dummy phase III 
clinical trial, compared direct FXa inhibitor apixaban to war-
farin in patients with AF and at least one additional risk factor 
for stroke. The primary endpoint was stroke, both ischemic 
and hemorrhagic stroke, or STE. Apixaban demonstrated a 
21% reduction in stroke or STE (P 0.01), a 31% reduction 
in major bleeding (P , 0.01), and an 11% reduction in all-
cause mortality (P 0.047). The reduced number of stroke 
with apixaban was mainly driven by the reduction of hemor-
rhagic stroke, a 50% reduction compared with warfarin. On 
ischemic stroke and uncertain stroke, there was essentially 
no difference with apixaban compared with warfarin. There 
was no increase in myocardial infarction; in fact, there 
was a trend toward a lower rate of myocardial infarction 
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  differentiating it from the other thrombin-inhibitor trials.72 
Table 8 compares the main findings of RE-LY, ROCKET AF, 
and ARISTOTLE trials.
Use of new OACs in clinical practice
The newer OACs, thrombin inhibitor (dabigatran) and FXa 
inhibitors (rivaroxaban, apixaban), come close in terms of 
the ideal properties in oral agents that the scientific com-
munity has been looking for. However, there are significant 
differences in pharmacokinetics and pharmacodynamics of 
these agents that an astute clinician should be aware of and 
are outlined in Table 9.73
Advantages of the newer agents  
over vKAs
The new OACs have faster onset and offset of action com-
pared to VKAs, obviating the need for bridging therapy. 
They have fixed dosing with predictable anticoagulation 
effect as opposed to VKAs, whose dosing is variable, 
requiring frequent coagulation tests and dose adjustment 
based on INR response. These agents have fewer food and 
drug interactions when compared to VKAs, meaning fewer 
dietary and drug precautions for patients. They have specific 
coagulation enzyme targets, which means low risk for off-
target adverse events.
Disadvantages/concerns with the use  
of newer agents over vKAs
Several clinical trials, as discussed above, have now shown that 
the new OACs, if not better, are as good as VKAs in prevent-
ing stroke in patients with AF. We cannot, however, overlook 
some potential problems with these newer agents. First, most 
of them have twice a day dosing for the indication of stroke 
prevention in AF as compared to once a day dosing with 
VKAs. How this will affect patient compliance is not known. 
While infrequent monitoring is a big advantage compared 
to VKAs, the drawback is that there is no tangible way yet 
to assess patient adherence, confirm adequacy of treatment, 
detect overdose/toxicity before it is too late, and last (but not 
least) a reassurance for the physicians and the patients that 
the drug is working. Unlike VKAs, most of these new agents 
are excreted by the kidneys to varying extents (25%–80%; 
Table 9), which could mean potential for accumulation in renal 
insufficiency and increased risk of bleeding. Dose adjustment 
in patients with renal insufficiency will therefore be crucial. 
All the major clinical trials have shown reduced incidence of 
intracranial hemorrhages with the newer agents compared 
to VKAs, bleeding nevertheless still remains an important 
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concern with the use of these agents. INR monitoring plays 
a crucial role in a bleeding patient on VKAs, absence of a 
similar clinical parameter to follow in patients who could 
bleed on these newer agents is concerning. Another major 
concern with the use of these newer agents is the lack of a 
clinically proven antidote. The half-lives of the newer agents 
vary anywhere from 6 hours to 18 hours (Table 9); lack of 
an antidote, like vitamin K therapy for VKAs, could mean 
continued bleeding for several hours in patients being treated 
with direct thrombin or FXa inhibitors. Although there are no 
antidotes currently available that could reverse the effect of the 
newer agents, fresh frozen plasma and prothrombin complex 
concentrate could be used in the settings of major bleeds.73 
In a small study on healthy individuals by Eerenberg et al 
prothrombin complex concentrate showed immediate and 
complete reversal of the anticoagulation effect of rivaroxaban 
but not that of dabigatran.74 While agents like prothrombin 
complex concentrate show a promise, before they are shown 
to be effective in large clinical trials and are widely available, 
clinicians will have to use both caution and clinical judgment 
with the use of the newer agents. Lastly, the newer agents have 
shown to be safe in the settings of clinical trials, however, their 
long-term safety when used in the real world is still a concern 
(and a valid one) until more data is available.
Conclusion
Prevention of stroke and STE has major implications from 
the mortality and morbidity perspectives in patients with AF. 
Despite overwhelming evidence of its clinical utility in pre-
vention of thromboembolism in AF patients, adjusted dose 
VKA agents (especially warfarin) have been challenging, 
leading to underutilization in otherwise at risk and eligible 
patients. The inadequacy of VKA therapy led to an active 
search for novel anticoagulant agents targeting different sites 
in the coagulation pathway. Some of these agents, namely 
the direct thrombin inhibitor dabigatran, and direct FXa 
inhibitors (apixaban and rivaroxaban) have recently been 
tested in phase III clinical trials and have shown promise, 
heralding an exciting phase in the field of AF and anticoagu-
lation, albeit with cautious optimism. These drugs appear 
to be non-inferior to warfarin. In fact, some show a trend 
towards even being superior. The question would be how to 
use these drugs in patients once they become more readily 
available. Some of the factors that will play a role in shaping 
our future clinical decision-making would include the ready 
availability of laboratory tests to measure the therapeutic 
effectiveness of these agents; availability of agents that 
could reverse the effect of these agents when needed; cost 
effectiveness compared to warfarin; patient preference, espe-
cially in case of those who are currently stable on warfarin 
therapy; safety of use in patients with renal insufficiency or 
those on dialysis; and safety and effectiveness in patients 
with mechanical valves. Due to the challenges associated 
with oral VKA therapy, many eligible Afib patients never 
get started on an OAC therapy. One possible advantage with 
the advent of these newer agents is that, it may reduce the 
Table 9 Pharmacokinetics and pharmacodynamics of new oral anticoagulant agents73
Dabigatran Rivaroxaban Apixaban
Target Thrombin Factor Xa Factor Xa
Prodrug Yes No No
Time to peak plasma  
concentration (hours)
2.3–2.9 2.5–4.0 5.8
Half-life (hours) 14–17 5.7–9.2 ∼12
Bioavailability 4%–5% 60%–80% 50%–85%
Dosing Twice a day 
(Once a day)
Once a day 
(Twice a day)
Twice a 
day
Food interference Acidic milieu needed for absorption;  
food and drugs increasing stomach/intestine  
pH may reduce absorption
Absorption increased  
by food
Not known
Drug interference Moderate. Especially with p-glycoprotein inhibitors  
(eg, verapamil) or inducers (eg, Rifampicin)
Low Low
Renal clearance 80% 65% 25%
Hepatic clearance 20% 28%–35% 75%
Need for dose adjustment  
with renal insufficiency
Yes Yes Possibly
Hepatotoxicity Unknown Unknown Unknown
Need for international normalized  
ratio monitoring
No No No
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threshold to start effective OAC therapy in otherwise eligible 
Afib patients in the primary care settings.
While the CHADS2 score is widely used and most 
validated of the RSMs, it has been shown to have its own 
shortcomings. The recently proposed CHA2DS2-VASc 
score shows promise and could definitely prove to be an 
important tool in the contentious group of patients with a 
CHADS2 score of 1, especially now with the availability of 
easy to use agents.
Bleeding risk assessment has always been felt to be 
important when starting AF patients on OAC therapy. While 
several bleeding RSMs were proposed over the years, none 
seemed easy to use and easy to remember in general clinical 
settings. The recently proposed HAS-BLED score and the 
ATRIA hemorrhage risk score are easy to remember, use 
readily available clinical parameters, have been validated in 
real-life AF patients, and could prove to be important tools 
in clinical decision making as far as AF and OAC therapy 
is concerned.
Disclosure
Dr Jhawar has no disclosures to make and reports no conflicts 
of interest in this work. Dr Flaker has research grants from 
Boeringer-Ingelheim, Sanofi-Aventis, Bristol-Myers Squibb 
and Pfizer. He is a consultant for the above companies.
References
1.  Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for develop-
ment of atrial fibrillation: the Framingham Heart Study. Circulation. 
2004;110(9):1042–1046.
2.  Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial 
fibrillation in adults: national implications for rhythm management and 
stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibril-
lation (ATRIA) Study. JAMA. 2001;285(18):2370–2375.
3.  Fuster V , Rydén LE, Cannom DS, et al; American College of Cardiology; 
American Heart Association Task Force; European Society of Cardiology 
Committee for Practice Guidelines; European Heart Rhythm Association; 
Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the 
management of patients with atrial fibrillation: full text: a report of 
the American College of Cardiology/American Heart Association Task 
Force on practice guidelines and the European Society of Cardiology 
Committee for Practice Guidelines (Writing Committee to Revise the 
2001 guidelines for the management of patients with atrial fibrillation) 
developed in collaboration with the European Heart Rhythm Association 
and the Heart Rhythm Society. Europace. 2006;8(9):651–745.
4.  Savelieva I, Bajpai A, Camm AJ. Stroke in atrial fibrillation: update 
on pathophysiology, new antithrombotic therapies, and evolution of 
procedures and devices. Ann Med. 2007;39(5):371–391.
5.  Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, 
Halperin JL. Stroke with intermittent atrial fibrillation: incidence and 
predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation 
Investigators. J Am Coll Cardiol. 2000;35(1):183–187.
6.  Hart RG, Halperin JL. Atrial fibrillation and stroke: concepts and con-
troversies. Stroke. 2001;32(3):803–808.
7.  Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol. 
2007;6(11):981–993.
  8.  Blackshear JL, Odell JA. Appendage obliteration to reduce stroke 
in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 
1996;61(2):755–759.
  9.  Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in 
atrial fibrillation: Virchow’s triad revisited. Lancet. 2009;373(9658): 
155–166.
  10.  Pollick C, Taylor D. Assessment of left atrial appendage function by 
transesophageal echocardiography. Implications for the development 
of thrombus. Circulation. 1991;84(1):223–231.
  11.  European Heart Rhythm Association; European Association for Cardio-
Thoracic Surgery. Guidelines for the management of atrial fibrillation: 
The Task Force for the Management of Atrial Fibrillation of the European 
Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–2429.
  12.  Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: 
a systematic review of stroke risk factors, risk stratification schema and 
cost effectiveness data. Thromb Haemost. 2008;99(2):295–304.
  13.  Stroke Risk in Altrial Fibrillation Working Group. Independent predic-
tors of stroke in patients with atrial fibrillation: a systematic review. 
Neurology. 2007;69(6):546–554.
  14.  Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, 
Radford MJ. Validation of clinical classification schemes for predicting 
stroke: results from the National Registry of Atrial Fibrillation. JAMA. 
2001;285(22):2864–2870.
  15.  Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke 
prevention in atrial fibrillation: how well do randomized trials translate 
into clinical practice? JAMA. 2003;290(20):2685–2692.
  16.  Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial 
fibrillation for anticoagulation: stroke risk stratification in patients taking 
aspirin. Circulation. 2004;110(16):2287–2292.
  17.  Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical 
risk stratification for predicting stroke and thromboembolism in atrial 
fibrillation using a novel risk factor-based approach: the euro heart 
survey on atrial fibrillation. Chest. 2010;137(2):263–272.
  18.  Gorin L, Fauchier L, Nonin E, et al. Antithrombotic treatment and 
the risk of death and stroke in patients with atrial fibrillation and a 
CHADS2 score = 1. Thromb Haemost. 2010;103(4):833–840.
  19.  Sato H. Low-dose aspirin for prevention of stroke in low-risk patients 
with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke. 
2006;37(2):447–451.
  20.  No authors listed. Transesophageal echocardiographic correlates of 
thromboembolism in high-risk patients with nonvalvular atrial fibrillation. 
The Stroke Prevention in Atrial Fibrillation Investigators Committee on 
Echocardiography. Ann Intern Med. 1998;128(8):639–647.
  21.  Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification 
schemes for predicting stroke and thromboembolism in patients with 
atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.
  22.  Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. 
Placebo-controlled, randomised trial of warfarin and aspirin for preven-
tion of thromboembolic complications in chronic atrial fibrillation. The 
Copenhagen AFASAK study. Lancet. 1989;1(8631):175–179.
  23.  No authors listed. The effect of low-dose warfarin on the risk of stroke 
in patients with nonrheumatic atrial fibrillation. The Boston Area Anti-
coagulation Trial for Atrial Fibrillation Investigators. N Engl J Med. 
1990;323(22):1505–1511.
  24.  No authors listed. Stroke Prevention in Atrial Fibrillation Study. Final 
results. Circulation. 1991;84(2):527–539.
  25.  Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. 
Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll 
Cardiol. 1991;18(2):349–355.
  26.  Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the 
prevention of stroke associated with nonrheumatic atrial fibrillation. 
Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation 
Investigators. N Engl J Med. 1992;327(20):1406–1412.
  27.  No authors listed. Secondary prevention in non-rheumatic atrial fibrilla-
tion after transient ischaemic attack or minor stroke. EAFT (  European 
Atrial Fibrillation Trial) Study Group. Lancet. 1993;342(8882): 
1255–1262.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
11
Atrial fibrillation and oral anticoagulationJournal of Blood Medicine 2012:3
  28.  Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy 
to prevent stroke in patients who have nonvalvular atrial fibrillation. 
Ann Intern Med. 2007;146(12):857–867.
  29.  Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European 
Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the 
secondary prevention of stroke. J Neurol Sci. 1996;143(1–2):1–13.
  30.  Posada IS, Barriales V . Alternate-day dosing of aspirin in atrial fibril-
lation. LASAF Pilot Study Group. Am Heart J. 1999;138(1 Pt 1): 
137–143.
  31.  Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom 
transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol 
Neurosurg Psychiatr. 1991;54(12):1044–1054.
  32.  Edvardsson N, Juul-Möller S, Omblus R, Pehrsson K. Effects of low-dose 
warfarin and aspirin versus no treatment on stroke in a medium-risk patient 
population with atrial fibrillation. J Intern Med. 2003;254(1):95–101.
  33.  No authors listed. Warfarin versus aspirin for prevention of thromboem-
bolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II 
Study. Lancet. 1994;343(8899):687–691.
  34.  Gulløv AL, Koefoed BG, Petersen P. Bleeding during warfarin and 
aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. 
Atrial Fibrillation Aspirin and Anticoagulation. Arch Intern Med. 
1999;159(12):1322–1328.
  35.  Hellemons BS, Langenberg M, Lodder J, et al. Primary prevention of 
arterial thromboembolism in non-rheumatic atrial fibrillation in primary 
care: randomised controlled trial comparing two intensities of coumarin 
with aspirin. BMJ. 1999;319(7215):958–964.
  36.  Vemmos KN, Tsivgoulis G, Spengos K, et al. Primary prevention of 
arterial thromboembolism in the oldest old with atrial fibrillation – a 
randomized pilot trial comparing adjusted-dose and fixed low-dose 
coumadin with aspirin. Eur J Intern Med. 2006;17(1):48–52.
  37.  Hu DY, Zhang HP, Sun YH, Jiang LQ; Antithrombotic Therapy in 
Atrial Fibrillation Study Group. The randomized study of efficiency 
and safety of antithrombotic therapy in nonvalvular atrial fibrillation: 
warfarin compared with aspirin. [Article in Chinese]. Zhonghua Xin 
Xue Guan Bing Za Zhi. 2006;34(4):295–298.
  38.  Rash A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS.   
A randomised controlled trial of warfarin versus aspirin for stroke 
prevention in octogenarians with atrial fibrillation (WASPO). Age 
Ageing. 2007;36(2):151–156.
  39.  Morocutti C, Amabile G, Fattapposta F, et al. Indobufen versus war-
farin in the secondary prevention of major vascular events in nonrheu-
matic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) 
  Investigators. Stroke. 1997;28(5):1015–1021.
  40.  Pérez-Gómez F, Alegría E, Berjón J, et al; NASPEAF Investigators. 
Comparative effects of antiplatelet, anticoagulant, or combined therapy 
in patients with valvular and nonvalvular atrial fibrillation: a randomized 
multicenter study. J Am Coll Cardiol. 2004;44(8):1557–1566.
  41.  Connolly S, Pogue J, Hart R, et al; ACTIVE Writing Group of the 
ACTIVE Investigators. Clopidogrel plus aspirin versus oral antico-
agulation for atrial fibrillation in the Atrial fibrillation Clopidogrel 
Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): 
a randomised controlled trial. Lancet. 2006;367(9526):1903–1912.
  42.  Connolly SJ, Pogue J, Hart RG, et al; ACTIVE Investigators. Effect of 
clopidogrel added to aspirin in patients with atrial fibrillation. N Eng J 
Med. 2009;360(20):2066–2078.
  43.  Eikelboom JW, Hirsh J. Combined antiplatelet and anticoagulant 
therapy: clinical benefits and risks. J Thromb Haemost. 2007;5 Suppl 1: 
255–263.
  44.  Dentali F, Douketis JD, Lim W, Crowther M. Combined aspirin-oral 
anticoagulant therapy compared with oral anticoagulant therapy alone 
among patients at risk for cardiovascular disease: a meta-analysis of 
randomized trials. Arch Intern Med. 2007;167(2):117–124.
  45.  Mant J, Hobbs FD, Fletcher K, et al; BAFTA Investigators; Midland 
Research Practices Network (MidReC). Warfarin versus aspirin for stroke 
prevention in an elderly community population with atrial fibrillation (the 
Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): 
a randomised controlled trial. Lancet. 2007;370(9586):493–503.
  46.  Nieuwlaat R, Capucci A, Lip GY, et al; Euro Heart Survey Investigators. 
Antithrombotic treatment in real-life atrial fibrillation patients:   
a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 
2006;27(24):3018–3026.
  47.  Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY.   
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major 
bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 
2010;138(5):1093–1100.
  48.  Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index 
for predicting the risk of major bleeding in outpatients treated with 
warfarin. Am J Med. 1998;105(2):91–99.
  49.  Kuijer PM, Hutten BA, Prins MH, Büller HR. Prediction of the risk of 
bleeding during anticoagulant treatment for venous thromboembolism. 
Arch Intern Med. 1999;159(5):457–460.
  50.  Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF. Combined 
anticoagulant-antiplatelet use and major bleeding events in elderly 
atrial fibrillation patients. Stroke. 2004;35(10):2362–2367.
  51.  Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes 
for predicting hemorrhage: results from the National Registry of Atrial 
Fibrillation (NRAF). Am Heart J. 2006;151(3):713–719.
  52.  Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a 
novel risk score for predicting bleeding risk in anticoagulated patients 
with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/
Liver Function, Stroke, Bleeding History or Predispostion, Labile INR, 
Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011; 
57(2):173–180.
  53.  Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict war-
farin-associated hemorrhage: The ATRIA (Anticoagulation and Risk 
Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58(4): 
395–401.
  54.  Wann LS, Curtis AB, Ellenbogen KA, et al; American College of 
Cardiology Foundation/American Heart Association Task Force. 
2011 ACCF/AHA/HRS focused update on the management of 
patients with atrial fibrillation (update on Dabigatran): a report 
of the American College of Cardiology Foundation/American 
Heart Association Task Force on practice guidelines. Circulation. 
2011;123(10):1144–1150.
  55.  Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The phar-
macology and management of the vitamin K antagonists: the Seventh 
ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 
2004;126(Suppl 3):204S–233S.
  56.  Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in 
outpatients taking warfarin. Ann Intern Med. 1994;120(11):897–902.
  57.  Odén A, Fahlén M, Hart RG. Optimal INR for prevention of stroke 
and death in atrial fibrillation: a critical appraisal. Thromb Res. 
2006;117(5):493–499.
  58.  Stafford RS, Singer DE. National patterns of warfarin use in atrial 
fibrillation. Arch Intern Med. 1996;156(22):2537–2541.
  59.  Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do 
patients with atrial fibrillation not receive warfarin? Arch Intern Med. 
2000;160(1):41–46.
  60.  Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer 
DE. Warfarin use among ambulatory patients with nonvalvular atrial 
fibrillation: the anticoagulation and risk factors in atrial fibrillation 
(ATRIA) study. Ann Intern Med. 1999;131(12):927–934.
  61.  Samsa GP, Matchar DB, Goldstein LB, et al. Quality of anticoagulation 
management among patients with atrial fibrillation: results of a 
review of medical records from 2 communities. Arch Intern Med. 
2000;160(7):967–973.
  62.  Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J. 
2007;29(2):155–165.
  63.  Bates SM, Weitz JI. The status of new anticoagulants. Br J Haematol. 
2006;134(1):3–19.
  64.  Olsson SB. Stroke prevention with the oral direct thrombin inhibitor 
ximelagatran compared with warfarin in patients with non-valvular 
atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 
2003;362(9397):1691–1698.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
12
Jhawar and FlakerJournal of Blood Medicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/Journal-of-blood-medicine-journal
The Journal of Blood Medicine is an international, peer-reviewed, open 
access, online journal publishing laboratory, experimental and clinical aspects 
of all topics pertaining to blood based medicine including but not limited to: 
Transfusion Medicine; Blood collection, Donor issues, Transmittable diseases, 
and Blood banking logistics; Immunohematology; Artificial and alternative 
blood based therapeutics; Hematology; Biotechnology/nanotechnology of 
blood related medicine; Legal aspects of blood medicine; Historical perspec-
tives. The manuscript management system is completely online and includes 
a very quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Journal of Blood Medicine 2012:3
  65.  Albers GW, Diener HC, Frison L, et al; SPORTIF Executive Steering 
Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin 
for stroke prevention in patients with nonvalvular atrial fibrillation:   
a randomized trial. JAMA. 2005;293(6):690–698.
  66.  Hermans C, Claeys D. Review of the rebound phenomenon in new 
anticoagulant treatments. Curr Med Res Opin. 2006;22(3):471–481.
  67.  Fiessinger JN, Huisman MV , Davidson BL, et al; THRIVE Treatment 
Study Investigators. Ximelagatran vs low-molecular-weight heparin 
and warfarin for the treatment of deep vein thrombosis: a randomized 
trial. JAMA. 2005;293(6):681–689.
  68.  Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee 
and Investigators. Dabigatran versus warfarin in patients with atrial 
fibrillation. N Engl J Med. 2009;361(12):1139–1151.
  69.  Bousser MG, Bouthier J, Büller HR, et al. Comparison of idraparinux 
with vitamin K antagonists for prevention of thromboembolism in 
patients with atrial fibrillation: a randomised, open-label, non-inferiority 
trial. Lancet. 2008;371(9609):315–321.
  70.  Connolly SJ, Eikelboom J, Joyner C, et al; AVERROES   Steering 
Committee and Investigators. Apixaban in patients with atrial fibrillation. 
N Engl J Med. 2011;364(9):806–817.
  71.  Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. 
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl 
J Med. 2011;365(10):883–891.
  72.  Granger CB, Alexander JH, McMurray JJ, et al; ARISTOTLE 
Committees and Investigators. Apixaban versus warfarin in patients 
with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
  73.  Merli G, Spyropoulos AC, Caprini JA. Use of emerging oral anticoagu-
lants in clinical practice: translating results from clinical trials to ortho-
pedic and general surgical patient populations. Ann Surg. 2009;250(2): 
219–228.
  74.  Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of 
rivaroxaban and dabigatran by prothrombin complex concentrate:   
a randomized, placebo-controlled, crossover study in healthy subjects. 
Circulation. 2011;124(14):1573–1579.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
13
Atrial fibrillation and oral anticoagulation